Denver’s Life Sciences Market Sees One of its Strongest Years Yet

Photo credit: Savills

The life sciences market continues to evolve as we enter 2025, and its real estate needs are changing as well. Rigid labs are being replaced by adaptable, collaborative spaces that foster innovation. The market demands spaces that meet diverse business needs and accommodate its changing workforce.

These are among the trends that the global real estate services firm Savills sees in the life sciences sector. Here are some key takeaways from the Q4 Life Sciences Tenant Report recently released by Savills:

  • As the life sciences sector evolves by integrating tech and data talent, workplace design is shifting to meet the needs of an interdisciplinary, sustainability-focused workforce.
  • Sublease availability is on the decline as listings expire and revert to landlords which is driving life sciences companies to consider more direct leasing options.
  • Venture capital (VC) funding in the life sciences industry rose to $44.8 billion in 2024, a 19.0% year-over-year increase from $37.7 billion in 2023, despite an 11.8% decline in the number of deals closed during the same period.

Some key highlights in the Denver-Boulder life sciences market overview include:

  • Venture capital funding in Denver-Boulder’s life sciences sector rose 28.4% from 2023 to 2024, marking one of its strongest years yet.
  • RefinedScience has chosen Fitzsimons Innovation Community in Aurora as its Colorado headquarters, moving from its incubator space to permanent facilities in Bioscience 3.
  • Boulder-based Ambrosia Biosciences raised $25.0 million in Series A funding, with $6.0 million from Merck. The startup develops oral therapies for obesity and metabolic disorders.

To read the full report, click here.

Related Posts

Scroll to Top